blog

F1000 Member Jacques Bernier is a radiation oncologist. Here at the ESMO ECCO meeting in Stockholm he tells us of recent developments in head and neck oncology, specifically chemoradiation, radiation therapy with targeted therapy (Cetuximab), and combinations of the two.

Chemoradiation therapy is significantly more efficacious than radiation therapy alone, but long-term complications in surviving patients are increased. Radiation therapy with Cetuximab is again superior therapeutically, and the long-term toxicity is not much higher than radiation therapy alone. Jacques talks about early Phase III results with combination therapy, and how he hopes to have some solid results next year.

We will know [how] to proceed with the combination of targeted therapies